Hims & Hers Health, Inc. (NYSE:HIMS) Receives $31.71 Average Target Price from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average recommendation of “Hold” by the seventeen brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $31.7143.

HIMS has been the topic of several recent analyst reports. Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and increased their price target for the company from $12.50 to $23.00 in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, March 10th. Truist Financial reiterated a “hold” rating and issued a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and increased their price target for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Friday, March 27th.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded GLP‑1 partnership and new weight‑loss membership: Hims renewed and broadened its collaboration with Novo Nordisk to offer a wider set of FDA‑approved GLP‑1 medicines (including Wegovy options) and launched a tiered weight‑loss membership (intro $39, then $149/month; meds priced separately). This expands prescription revenue potential and recurring revenue mix. Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership – Has The Bull Case Changed?
• Positive Sentiment: Platform expansion (Labs, hormone therapy, weight programs): Management is broadening the digital‑first care offering to increase average revenue per customer and lifetime value as it scales internationally. This supports longer‑term growth and customer engagement. Hims & Hers Advances a Consumer-Centric Digital Health Platform
• Neutral Sentiment: Analyst/sector commentary: Contrarian coverage highlights HIMS as a consumer momentum play despite regulatory noise — a sentiment piece that can attract value‑oriented buyers but is not a catalyst by itself. 3 Sectors to Buy While They’re Down and 1 to Walk Away From
• Neutral Sentiment: Insider sale disclosed: CFO Oluyemi Okupe sold ~3,975 shares under a pre‑arranged Rule 10b5‑1 plan. The sale reduced his stake slightly but was planned in advance, which lessens the negative signal. Insider Sale Filing
• Neutral Sentiment: Price action note: Coverage flagged a recent intraday dip in the stock — reflects short‑term volatility and mixed newsflow rather than a single clear fundamental shift. Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Tariff risk to drug partnership: Reporting warns of a new tariff that could threaten a key drug partnership and margin profile if it affects medication sourcing or pricing — this is a material regulatory/ policy risk to the prescription side of the business. Hims & Hers Faces Dual Challenges: New Tariff Threatens Key Drug Partnership
• Negative Sentiment: Customer‑service platform breach: Hims reported a social‑engineering incident on a third‑party customer service platform with limited customer data exposure; medical records were not affected. Still, any breach raises reputational and compliance risk and could increase costs (security, notifications, potential regulatory scrutiny). Hims & Hers says limited data stolen in social engineering attack

Insider Activity at Hims & Hers Health

In related news, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the transaction, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. This trade represents a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,812 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $118,808.28. Following the transaction, the insider directly owned 308,831 shares in the company, valued at approximately $7,625,037.39. This represents a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 129,889 shares of company stock worth $3,230,986. 13.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC raised its holdings in Hims & Hers Health by 427.1% in the 4th quarter. Hsbc Holdings PLC now owns 33,582 shares of the company’s stock valued at $1,090,000 after acquiring an additional 27,211 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in Hims & Hers Health by 13.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 41,088 shares of the company’s stock valued at $1,334,000 after buying an additional 4,980 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Hims & Hers Health in the 4th quarter valued at about $80,000. SHP Wealth Management bought a new position in Hims & Hers Health in the 4th quarter valued at about $106,000. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Hims & Hers Health by 413.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock valued at $559,000 after buying an additional 13,873 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 3.9%

HIMS opened at $19.54 on Friday. The stock has a market capitalization of $4.45 billion, a P/E ratio of 38.31, a P/E/G ratio of 2.31 and a beta of 2.32. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The firm’s fifty day simple moving average is $20.26 and its 200 day simple moving average is $34.02. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter in the prior year, the company posted $0.11 earnings per share. The firm’s revenue was up 28.4% on a year-over-year basis. As a group, research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.